ALS Untangled Series Ep. 49 - Methylcobalamin

enFebruary 08, 2023

CReATe Podcast

What was the main topic of the podcast episode?

Summarise the key points discussed in the episode?

Were there any notable quotes or insights from the speakers?

Which popular books were mentioned in this episode?

Were there any points particularly controversial or thought-provoking discussed in the episode?

Were any current events or trending topics addressed in the episode?

What was the main topic of the podcast episode?

Summarise the key points discussed in the episode?

Were there any notable quotes or insights from the speakers?

Which popular books were mentioned in this episode?

Were there any points particularly controversial or thought-provoking discussed in the episode?

Were any current events or trending topics addressed in the episode?

About this Episode

Methylcobalamin is a specific precursor to B12 (cobalamin). It has promising mechanisms by which it could slow ALS progression. Two trials done in Japan suggest that 50mg via intramuscular injection twice weekly can slow ALS progression and prolong survival. Here we discuss the evidence for ultra-high dose methylcobalamin in patients with ALS and conclude that it may offer benefit, but only if administered within the first year of symptoms. If started after the first year, there is no evidence of benefit. It appears reasonably safe.

Recent Episodes from CReATe Podcast

CReATe Author Series Ep. 10 - Drs. McHutchison and Benatar on Cognitive and Behavioral Changes in MND

Dr. Caroline McHutchison is a Neuropsychologist and CReATe Clinical Research Scholar at the University of Edinburgh and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication âTemporal course of cognitive and behavioural changes in motor neuron diseasesâ.

enFebruary 15, 2024

CReATe Author Series Ep. 9 - Drs. Heatwole and Benatar on Patient Reported Outcome Measures and ALS

Dr. Chad Heatwole is a Professor of Neurology and the Director of the Center for Health and Technology at the University of Rochester Medical Center and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication âThe amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measureâ and its role as a patient reported outcome measure for ALS.

enJanuary 03, 2024

ALS Untangled Series Ep. 56 - Sodium Chlorite

Sodium chlorite is an experimental drug targeting macrophage activation. It exists in different formulations. An oral formulation has potentially deadly side effects. An IV formulation called NP001 has been in recent trials targeting a subset of people with ALS. Here we review the interesting development of this product and where we expect that to go in the near future.

enNovember 15, 2023

ALS Untangled Series Ep. 55 - Rituximab

Rituximab is an intravenous product that reduces B lymphocytes. It can help improve strength in patients with myasthenia gravis and multi-focal motor neuropathy, neuromuscular diseases that are caused by circulating antibodies made by B lymphocytes. In this podcast we examine the possible use of rituximab to treat patients with ALS

enOctober 09, 2023

ALS Untangled Series Ep. 54 - Ozone Therapy

Ozone is an oxidizing agent which has some surprisingly plausible mechanisms by which it could influence ALS progression. It can also be dangerous. The FDA has warned against using it as a treatment for any disease. Further studies are needed to determine whether there is any dose or route of administration that might be safe and effective for use in people with ALS.

enSeptember 05, 2023

ALS Untangled Series Ep. 53 - Astaxanthin

Astaxanthin is a naturally occurring chemical which has plausible mechanisms for treating ALS and appears reasonably safe and well tolerated in non-ALS trials. We look forward to ALS-specific trials planned later this year which should shed important light on whether this is specifically safe for people with ALS, and whether it really can slow ALS progression.

enAugust 08, 2023

CReATe Author Series Ep. 8 Part I - Drs. Turner and Benatar on Neurofilament Light Chain as Biomarker for ALS

Dr. Martin Turner is a Professor of Clinical Neurology & Neurosciences at the University of Oxford and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication âNeurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisalâ, and the potential role of NfL as a biomarker for ALS. This is part I of a two part series.

enJune 12, 2023

CReATe Author Series Ep. 8 Part II - Drs. Turner and Benatar on Neurofilament Light Chain as Biomarker for ALS

enJune 12, 2023

ALS Untangled Series Ep. 52 - Antimycobacterial Antibiotics

There is a theorized association between mycobacteria and ALS, and two published case reports described improvements in ALS-like conditions (both with atypical features) after treatment with antimycobacterial antibiotics. Here we review these in detail and discuss our thoughts on how they might change our approach in certain patients in the future.

enMay 01, 2023

ALS Untangled Series Ep. 51 - Corticosteroids

Corticosteroids are a class of medications with well-studied effects on the immune system and some people living with ALS have reported benefits from them online. Here we review the pre-clinical and clinical data. We conclude that there is currently no clear evidence that steroids can slow ALS progression, and they can have many side effects.

enApril 03, 2023

Ask this episode Anything

What was the main topic of the podcast episode?

Summarise the key points discussed in the episode?

Were there any notable quotes or insights from the speakers?

Which popular books were mentioned in this episode?

Were there any points particularly controversial or thought-provoking discussed in the episode?

Were any current events or trending topics addressed in the episode?